Biomarkers of disease
The present invention relates to methods for the diagnosis and treatment of melanoma. In particular, the invention relates to methods for the diagnosis and treatment of early stage melanoma by measuring the expression of one or more autoantibodies selected from the group consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8_tv2, anti-MSN and anti-TPM1. Further, the present invention relates to kits comprising one or more reagents and/or devices when used in performing the methods for the diagnosis and treatment of melanoma.
1. A method of treating a subject with melanoma, wherein the melanoma is Stage 0, Stage I or Stage II melanoma, the method comprising the steps of:
a. measuring the expression levels of a group of autoantibodies including anti-ZBTB 7 B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8_tv2, anti-MSN and anti-TPM1 in a biological sample obtained from a subject;
b. comparing the levels of expressions of all of the autoantibodies in the group in the biological sample to reference values, wherein the reference values are representative of known or predetermined levels of the same autoantibodies in a reference sample or a plurality of reference samples from a subject or subjects that have never been diagnosed with cancer, melanoma or an autoimmune disease, wherein the expression levels of all of the autoantibodies in the group in the biological sample greater than the reference value provides an indication that the subject has melanoma;
c. identifying a subject that has melanoma from step (b); and
d. treating the subject identified in step (c) as having melanoma with a therapeutic regimen for preventing or delaying the progression of the melanoma, wherein the therapeutic regimen is selected from the group consisting of surgery, administration of a chemotherapeutic agent, radiotherapy, immunotherapy and targeted molecular therapy.
2. The method of claim 1 , wherein the step of measuring the expression levels of the autoantibodies in the biological sample comprises measuring the levels of protein expression of the autoantibodies in the biological sample.
3. The method of claim 2 , wherein the levels of protein expression are measured using multiplexed protein expression analysis.
4. The method of claim 3 , wherein the multiplexed protein expression analysis method is protein microarray or Luminex bead array.
5. The method of claim 1 , wherein the biological sample is a blood sample or a component of the blood sample.
6. The method of claim 5 , wherein the component of the blood sample is serum.
7. The method of claim 5 , wherein the component of the blood sample is plasma.
8. The method of claim 1 , wherein the therapeutic regimen comprises surgery.
9. The method of claim 8 , wherein the therapeutic regimen further comprises the administration of one or more or all of a chemotherapeutic agent, radiotherapy, immunotherapy and targeted molecular therapy.